Biologic Therapies for Severe Asthma

Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-01, Vol.386 (2), p.157-171
Hauptverfasser:	Brusselle, Guy G, Koppelman, Gerard H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adolescent Medicine Adult Algorithms Allergens Allergies Allergy Anaphylaxis Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Asthma Asthma - immunology Asthma - physiopathology Asthma - therapy Biological Therapy Biomarkers Biomarkers - blood Biopsy Child Childhood Diseases Chronic obstructive pulmonary disease Clinical Medicine Clinical Medicine General Critical Care Critical Care General Cytokines Descriptive labeling FDA approval Humans Immunology Immunology General Inflammation Interleukin-4 Receptor alpha Subunit - antagonists & inhibitors Interleukin-5 - antagonists & inhibitors Lung - physiopathology Medical prognosis Monoclonal antibodies Patient Acuity Pediatrics Pediatrics General Pulmonary Quality of life Teenagers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMra2032506